News
UK pilots shorter NICE appraisal for new medicines
NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.
News
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod
The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.
News
Bayer's Hyrnuo moves first-line for lung cancer in China
Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News
NICE backs Keytruda/Padcev combo for bladder cancer
Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
News
What do midterms mean for Trump's pharma and health agenda?
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
